Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Synagis 50mg Injection
Manufacturer/Marketed By : ASTRAZENECA PHARMA INDIA LTD
$196.56 $161.18
Synagis 50mg Injection contains the active substance Palivizumab, a monoclonal antibody used primarily to prevent severe respiratory syncytial virus (RSV)-related lower respiratory tract infections in high-risk children. Synagis 50mg Injection...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
PALIVIZUMAB
Active Pharmaceutical Ingredient
Synagis 50mg Injection
$196.56
$161.18
Synagis 50mg Injection contains the active substance Palivizumab, a monoclonal antibody used primarily to prevent severe respiratory syncytial virus (RSV)-related lower respiratory tract infections in high-risk children. Synagis 50mg Injection is prescribed to infants and young children at high risk for severe RSV infection, including those born prematurely (≤35 weeks gestational age), those with bronchopulmonary dysplasia (BPD), and children with hemodynamically significant congenital heart disease (CHD). It works by inhibiting the RSV F protein, preventing the virus from entering and infecting healthy cells. Before starting treatment with Synagis 50mg Injection, inform your doctor if your child has any history of allergies or bleeding disorders, as well as any other medications they are currently taking. While Synagis 50mg Injection is generally well-tolerated, regular monitoring is recommended, particularly for any signs of hypersensitivity reactions or coagulation disorders.
Active Pharmaceutical Ingredient
Uses
• Children with bronchopulmonary dysplasia (BPD)
• Infants born prematurely (≤35 weeks gestational age)
• Children with hemodynamically significant congenital heart disease (CHD)
Benefits
Synagis 50mg Injection is a recombinant humanised monoclonal antibody that provides passive immunity against RSV by binding to the RSV F protein on the virus surface. This action blocks a critical step in the fusion process and prevents RSV-infected cells from fusing with neighbouring cells, thus inhibiting the spread of the virus.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Most Common Side Effects
• Anaphylaxis (severe allergic reactions, including shock)
• Respiratory issues (e.g., dyspnea, respiratory failure, cyanosis)
• Hypotension (low blood pressure)
• Severe thrombocytopenia (low platelet count)
• Coagulation disorders (increased bleeding risk)
• Severe hypersensitivity reactions (e.g., angioedema, unresponsiveness)
Common Side Effects
• Fever
• Rash
• Injection site reactions (e.g., pain, swelling)
• Mild hypersensitivity reactions (e.g., urticaria, pruritus)
How To Use
Synagis 50mg Injection should be administered intramuscularly at a dose of 15 mg per kg, preferably in the anterolateral thigh. Inspect the vial for any particulate matter or discolouration before use and discard if found. Withdraw the dose using a sterile technique and administer it immediately. For doses over 1 mL, divide the dose. Do not re-enter the vial or reuse syringes and needles. Ensure a healthcare professional administers the drug for proper technique and safety.
Safety Advice
• Breast Feeding: Synagis 50mg Injection is not indicated for use in adults. Consult your healthcare provider before use if you are breastfeeding, as it’s important to weigh the potential risks and benefits.
• Alcohol: It is unknown whether it is safe to use Synagis 50mg Injection while consuming alcohol. Consult your doctor before taking this medication.
• Liver: You need to inform your doctor if you have any liver disorders before starting Synagis 50mg Injection.
• Lungs: Before starting treatment with Synagis 50mg Injection, talk to your doctor if you have any lung conditions.
• Driving: Synagis 50mg Injection is not indicated for use in adults. Please consult your healthcare provider for advice before engaging in activities such as driving.
• Pregnancy: Synagis 50mg Injection is not safe for use during pregnancy as it may cause fetal harm or could affect reproductive capacity when administered to a pregnant woman.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.